| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/22/2002 | US20020115649 Use of texaphyrins in macrophage-mediated disease |
| 08/22/2002 | US20020115648 Compositions comprising ethisterone or its derivatives |
| 08/22/2002 | US20020115645 Stabilized aqueous suspensions for parenteral use |
| 08/22/2002 | US20020115644 Tetracycline compounds for treatment of Cryptosporidium parvum related disorders |
| 08/22/2002 | US20020115643 Such as enantiomorphs of 4-fluorostyryl-2,3,4,5,6-pentafluorobenzylsulfone; antiproliferative/anticancer agents |
| 08/22/2002 | US20020115641 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 08/22/2002 | US20020115639 Glucosamine and method of making glucosamine from microbial blomass |
| 08/22/2002 | US20020115638 Method of forming a barrier on an epidermal surface |
| 08/22/2002 | US20020115636 Composition for treating equine gastric ulcers |
| 08/22/2002 | US20020115635 Modulation of GSK-3beta activity and its different uses |
| 08/22/2002 | US20020115632 Administering an effective amount of DNA in a vehicle in a manner so as not to effect gene transfer; cystic fibrosis, emphysema, chronic bronchitis, sinusitis, and the common cold; |
| 08/22/2002 | US20020115626 Comparing the expression of the nucleic acid encoding an antileuko-protease polypeptide of a cell population to the expression of a nucleic acid encoding the same peptide in an inflammation positive reference profile; enzyme inhibitors |
| 08/22/2002 | US20020115624 Such as alpha-galactosylceramide and alpha-glucosylceramide; screening method to identify putative alpha-glycosylceramide molecules that can stimulate NKT cells through a CD1d mechanism; detecting a shift toward a Th1 response |
| 08/22/2002 | US20020115622 Therapeutic agent for mastitis of livestock and method for treating mastitis using the same agent |
| 08/22/2002 | US20020115621 Macrolide antibiotics |
| 08/22/2002 | US20020115620 6-0-carbamoyl ketolide antibacterials |
| 08/22/2002 | US20020115619 Compositions and methods for treatment of cystic fibrosis |
| 08/22/2002 | US20020115618 Comprising a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor, antioxidant and carrier; side effect reduction; partial recovery of neurological function in some cases |
| 08/22/2002 | US20020115617 Methods for the prevention and / or the treatment of glutamate cytotoxicity |
| 08/22/2002 | US20020115612 High-speed automated solid-phase synthesis repeating steps of acylation of a resin-bound secondary amine with haloacetic acid followed by nucleophilic displacement of the halogen by an N-substituted amine; libraries |
| 08/22/2002 | US20020115603 Methods and compositions for the treatment of peripheral artery disease |
| 08/22/2002 | US20020115600 Inhibitors of memapsin 2 and use thereof |
| 08/22/2002 | US20020115598 Method for the improvement of neuronal regeneration |
| 08/22/2002 | US20020115595 Bioactive agent is covalently conjugated to an organocobalt complex's cobalt atom through a non-reactive atom in the bioactive agent molecule such as peptide, protein, nucleic acid and analogues |
| 08/22/2002 | US20020115587 Instillation techniques for ophthalmic agents to enhance treatment effect |
| 08/22/2002 | US20020115586 Contacting hematopoietic tissue with inhibitor(s) of nitric oxide synthase, to increase population of hematopoietic stem cells capable of undergoing normal hematopoiesis, differentiation and maturation |
| 08/22/2002 | US20020115223 In vitro system for determining formation of abeta amyloid |
| 08/22/2002 | US20020115203 Proteins for use in the treatment infectious, cancers and autoimmune disease |
| 08/22/2002 | US20020115183 Enzymatic protien for us ein prevention of tumor metastasis |
| 08/22/2002 | US20020115158 Novel microorganism isolated from chinese elm (Ulmus sp.) and process for preparing exopolysaccharides by employing the microorganism |
| 08/22/2002 | US20020115156 Connective tissue growth factor for use in the treatment of cancer, fibrotic defects and atherosclerosis; for use as wound healing agents |
| 08/22/2002 | US20020115140 Nucleotide sequences coding preferential polypeptide for use in treatment of immmunological defects |
| 08/22/2002 | US20020115138 Nucleotide sequences coding transport protein for use in treat ment of tumors |
| 08/22/2002 | US20020115121 Compositions and methods for detecting pre-cancerous conditions in cell and tissue samples using 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine |
| 08/22/2002 | US20020115111 Enzymatic polypeptide for use in the treatment of inflammation |
| 08/22/2002 | US20020115097 Determining the number of thymidine-adenine repeats that correlates with the expression of the glucuronosyltransferase (UGT) gene |
| 08/22/2002 | US20020115090 Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 08/22/2002 | US20020114846 For protecting against effects of Tumor Necrosis Factor (TNF); for protecting cardiomyocytes in a cell; for producing inhibitory A2-phospholipase activity; for normalizing biochemical parameters of liver function |
| 08/22/2002 | US20020114844 Particle formation methods and their products |
| 08/22/2002 | US20020114843 Placing the quantity of microparticles into a container; maintaining the microparticles at a conditioning temperature for a period of time |
| 08/22/2002 | US20020114842 Use of amoxycillin and clavulanate in the manufacture of a medicament for the empiric treatment of infections caused by drug-resistant streptococcus pneumo-nia |
| 08/22/2002 | US20020114839 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
| 08/22/2002 | US20020114837 Galenic composition for low bioavailability medicaments |
| 08/22/2002 | US20020114836 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 08/22/2002 | US20020114835 Administering at a site biocompatible, biodegradable, biodegradable, controlled release formulation comprising a local anesthetic, being present in a concentration effective to induce a localized condition |
| 08/22/2002 | US20020114831 Pharmaceutical formulation |
| 08/22/2002 | US20020114827 Methods and apparatus for improved administration of analgesics |
| 08/22/2002 | US20020114819 External dermal agent |
| 08/22/2002 | US20020114811 Contacting body fluid from mammal with antibody which binds to human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form antigen-antibody complex and detecting complex |
| 08/22/2002 | US20020114810 Diagnosis and treatment of malignant neoplasms statement as to federally sponsored research |
| 08/22/2002 | US20020114809 Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 08/22/2002 | US20020114803 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 08/22/2002 | US20020114796 Wound healing agents comprising fibrinogen, fibrin, thrombin, transglutaminase, and serpin protease inhibitor which doesn not inhibit collagenase and elastase in blood plasma |
| 08/22/2002 | US20020114792 Alpha-2-macroglobulin therapies and drug screening methods for Alzheimer's disease |
| 08/22/2002 | US20020114786 Pharmaceutical preparations comprising soybean isoflavone extracts and probiotic microogranisms |
| 08/22/2002 | US20020114781 Interleukin antagonists for suppressing autoimmune respone via reducing number of antigen-reactive lymphocytes; treatment of rheumatic diseases |
| 08/22/2002 | US20020114777 Cationic quaternery ammonium containing polymers for treatment of gastrointestinal disorders; cytotoxicity |
| 08/22/2002 | US20020114776 Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate |
| 08/22/2002 | US20020114774 Ionic polymers as toxin-binding agents |
| 08/22/2002 | US20020114770 For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits |
| 08/22/2002 | DE10108271A1 Chinolin-, Isochinolin- und Phthalazinderivate als Antagonisten des Gonadotropin freisetzenden Hormons Quinoline, isoquinoline and phthalazine derivatives releasing as antagonists of gonadotropin hormone |
| 08/22/2002 | DE10108215A1 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym A pharmaceutical combination of antagonists of angiotensin II inhibitors and angiotensin II converting enzyme |
| 08/22/2002 | DE10107639A1 2-Alkoxyphenyl-substituierte Imidazotriazinone 2-alkoxy-phenyl-substituted imidazotriazinones |
| 08/22/2002 | DE10100053A1 Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen Use of enzyme inhibitors of the dipeptidyl peptidase IV as well as the aminopeptidase N and pharmaceutical preparations thereof for the prevention and / or therapy of ischemia-related acute and chronic neurodegenerative diseases and processes |
| 08/22/2002 | CA2666611A1 Novel succinate salt of o-desmethyl-venlafaxine |
| 08/22/2002 | CA2533400A1 Cannabinoids pharmaceutical formulations |
| 08/22/2002 | CA2438712A1 Method of treating of demyelinating diseases or conditions |
| 08/22/2002 | CA2438707A1 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders |
| 08/22/2002 | CA2438656A1 Method for the prevention of tissue elastic fiber injury |
| 08/22/2002 | CA2438641A1 Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| 08/22/2002 | CA2438590A1 Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1 |
| 08/22/2002 | CA2438551A1 Ppar agonists |
| 08/22/2002 | CA2438492A1 Proliferative activator receptor (ppar) compounds |
| 08/22/2002 | CA2438219A1 Sequences involved in phenomena of tumour suppression, tumour reversion apoptosis and/or virus resistance and their use as medicines |
| 08/22/2002 | CA2438113A1 2-alkoxyphenyl substituted imidazotriazinones |
| 08/22/2002 | CA2437890A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 08/22/2002 | CA2437870A1 Radiation cross-linked hydrogels |
| 08/22/2002 | CA2437823A1 Acrochordon alleviation |
| 08/22/2002 | CA2437809A1 Novel alkyl phenylimino-imidazolidine derivatives for treating urinary incontinence |
| 08/22/2002 | CA2437768A1 Targetted anti-tumor drug delivery systems |
| 08/22/2002 | CA2437731A1 A medicinal composition and use comprising turmeric extract for smoke detoxification |
| 08/22/2002 | CA2437643A1 Matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2437588A1 Triazolo compounds as mmp inhibitors |
| 08/22/2002 | CA2437578A1 Carotenoid-loaded liposomes |
| 08/22/2002 | CA2437576A1 Method for evaluating therapeutic efficacy |
| 08/22/2002 | CA2437402A1 New crystal forms of oxcarbazepine and processes for their preparation |
| 08/22/2002 | CA2437358A1 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 08/22/2002 | CA2437333A1 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 08/22/2002 | CA2437122A1 Quinazolines as mmp-13 inhibitors |
| 08/22/2002 | CA2437118A1 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 08/22/2002 | CA2436713A1 Proteins and nucleic acids encoding same |
| 08/22/2002 | CA2436452A1 A compound and method of treatment for fungal pathologies of the oral cavity |
| 08/22/2002 | CA2436371A1 Bicyclic pyrimidine matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2436195A1 Laulimalide derivatives |
| 08/22/2002 | CA2436176A1 Thrombin inhibitors |
| 08/22/2002 | CA2436079A1 Heterocyclic inhibitors of glycine transporter 2 |
| 08/22/2002 | CA2436068A1 Thrombin inhibitors |
| 08/22/2002 | CA2435376A1 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2434982A1 Pyridine matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2434976A1 Medicament formulation containing a muscarinic agonist |